Rockwell Medical Misses Profit Target, Reports Q4 Loss

Edgen Stock

·Mar 26 2026, 12:26

Share to

Share to

Copy link

Key Takeaways

Rockwell Medical reported a fourth-quarter net loss of $0.01 per share, surprising analysts who had forecast a profit of $0.04 per share. The result represents a narrower loss than the $0.02 per share reported in the same quarter a year ago, but weak forward guidance suggests growth challenges.

Earnings Miss: The company posted a Q4 loss of $554,000, or $0.01 per share, against a consensus estimate for a $0.04 per share profit.
Revenue Details: Quarterly revenue came in at $18.3 million, contributing to a full-year 2025 total of $69.3 million.
Stagnant Outlook: Management issued full-year 2026 revenue guidance of $65 million to $70 million, suggesting flat to slightly negative growth ahead.

Rockwell Posts $554K Q4 Loss, Missing Profit Estimates

Rockwell Medical (RMTI) announced on March 26 a fourth-quarter net loss of $554,000, or $0.01 per share. This result significantly missed the Zacks Consensus Estimate, which had projected a profit of $0.04 per share. While the loss narrowed from the $0.02 per share loss recorded in the same period a year ago, the failure to achieve expected profitability is a key headwind for the stock.

Revenue Hits $18.3M as Guidance Signals Stagnation

The maker of products for kidney disease treatment generated revenue of $18.3 million for the fourth quarter. For the full year, Rockwell reported total revenue of $69.3 million and an annual loss of $5.3 million, or $0.15 per share. Looking ahead, the company's guidance for the next fiscal year projects revenue in a range of $65 million to $70 million. This forecast, which at its midpoint is below the just-completed year's revenue, indicates a potential for flat to slightly declining top-line performance and casts doubt on the company's near-term growth prospects.